{"id":32731,"date":"2011-01-06T14:12:27","date_gmt":"2011-01-06T14:12:27","guid":{"rendered":"http:\/\/localhost:8888\/wordpress\/inhalers_recalled_due_to_misla\/"},"modified":"2024-12-17T15:48:39","modified_gmt":"2024-12-17T20:48:39","slug":"inhalers-recalled-due-to-misla","status":"publish","type":"post","link":"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/","title":{"rendered":"Inhalers Recalled Due To Mislabeling"},"content":{"rendered":"

The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled outer packaging is generally discarded.<\/p>\n

Health care providers seeing only the mislabeled bottle would be very likely to give the wrong dose, especially since the two solution strengths are distilled in equal sized bottles. The .05 mg\/3 ml bottles look just like the 2.5 mg.\/ 3 ml bottles. Only the strength differs.<\/p>\n

Albuterol Sulfate Inhalation is sold in single use dosage bottles, in 25, 30 and 60 count unit dose packages. Recalled Albuterol was sold nationwide in the United States and in Puerto Rico.<\/p>\n

Continue reading<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled outer packaging is generally discarded. Health care providers seeing only the mislabeled bottle would be very likely to give the wrong dose, especially since the two solution strengths are distilled in equal […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[44],"class_list":["post-32731","post","type-post","status-publish","format-standard","hentry","category-personal-injury-wrongful-death","tag-personal-injury"],"yoast_head":"\nInhalers Recalled Due To Mislabeling — Trial Attorney Blog — January 6, 2011<\/title>\n<meta name=\"description\" content=\"The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled — January 6, 2011\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Inhalers Recalled Due To Mislabeling — Trial Attorney Blog — January 6, 2011\" \/>\n<meta name=\"twitter:description\" content=\"The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled — January 6, 2011\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Finch McCranie, LLP\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhalers Recalled Due To Mislabeling — Trial Attorney Blog — January 6, 2011","description":"The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled — January 6, 2011","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/","twitter_card":"summary_large_image","twitter_title":"Inhalers Recalled Due To Mislabeling — Trial Attorney Blog — January 6, 2011","twitter_description":"The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled — January 6, 2011","twitter_misc":{"Written by":"Finch McCranie, LLP","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/","url":"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/","name":"Inhalers Recalled Due To Mislabeling — Trial Attorney Blog — January 6, 2011","isPartOf":{"@id":"https:\/\/www.finchmccranie.com\/blog\/#website"},"datePublished":"2011-01-06T14:12:27+00:00","dateModified":"2024-12-17T20:48:39+00:00","author":{"@id":"https:\/\/www.finchmccranie.com\/blog\/#\/schema\/person\/4c607d19a3fdb947c462210c077ff4a4"},"description":"The Food and Drug Administration is also concerned that hospital, med-center and emergency patients may be given the higher dose, as correctly labeled — January 6, 2011","breadcrumb":{"@id":"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.finchmccranie.com\/blog\/inhalers-recalled-due-to-misla\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.finchmccranie.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Inhalers Recalled Due To Mislabeling"}]},{"@type":"WebSite","@id":"https:\/\/www.finchmccranie.com\/blog\/#website","url":"https:\/\/www.finchmccranie.com\/blog\/","name":"Trial Attorney Blog","description":"Published by Georgia Trial Lawyers \u2014 Finch McCranie, LLP","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.finchmccranie.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.finchmccranie.com\/blog\/#\/schema\/person\/4c607d19a3fdb947c462210c077ff4a4","name":"Finch McCranie, LLP","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.finchmccranie.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0ac10eb5fe0f322f70ad7a84f6c73584e7381799013c841fb9f2ecf347e28d71?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ac10eb5fe0f322f70ad7a84f6c73584e7381799013c841fb9f2ecf347e28d71?s=96&d=mm&r=g","caption":"Finch McCranie, LLP"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts\/32731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/comments?post=32731"}],"version-history":[{"count":1,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts\/32731\/revisions"}],"predecessor-version":[{"id":32962,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts\/32731\/revisions\/32962"}],"wp:attachment":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/media?parent=32731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/categories?post=32731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/tags?post=32731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}